Paul Andrew Moore Net Worth

The estimated Net Worth of Paul Andrew Moore is at least $208 Thousand dollars as of 5 January 2024. Paul Moore owns over 17,166 units of Zymeworks BC Inc stock worth over $207,709 and over the last 2 years Paul sold ZYME stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Paul Moore ZYME stock SEC Form 4 insiders trading

Paul has made over 1 trades of the Zymeworks BC Inc stock since 2024, according to the Form 4 filled with the SEC. Most recently Paul exercised 17,166 units of ZYME stock worth $207,709 on 5 January 2024.

The largest trade Paul's ever made was exercising 17,166 units of Zymeworks BC Inc stock on 5 January 2024 worth over $207,709. On average, Paul trades about 5,722 units every 0 days since 2022. As of 5 January 2024 Paul still owns at least 17,166 units of Zymeworks BC Inc stock.

You can see the complete history of Paul Moore stock trades at the bottom of the page.

What's Paul Moore's mailing address?

Paul's mailing address filed with the SEC is C/O ZYMEWORKS INC., 108 PATRIOT DRIVE, SUITE A, MIDDLETOWN, DE, 19709.

Insiders trading at Zymeworks BC Inc

Over the last 6 years, insiders at Zymeworks BC Inc have traded over $15,586,802 worth of Zymeworks BC Inc stock and bought 5,881,975 units worth $49,789,204 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., Capital, Llc Eco R1, and Group, Llc Green Jeremy Red.... On average, Zymeworks BC Inc executives and independent directors trade stock every 37 days with the average trade being worth of $1,629,555. The most recent stock trade was executed by Kenneth Galbraith on 5 January 2024, trading 47,666 units of ZYME stock currently worth $576,759.

What does Zymeworks BC Inc do?

zymeworks is a privately held biotherapeutics company that is developing best-in-class azymetric™ bi specific antibodies and antibody drug conjugates for the treatment of oncology, autoimmunity and inflammatory diseases. the company’s novel azymetric™ and albucore™ platforms, and its proprietary zymecad™ structure-guided protein engineering technology, enable the development of highly potent bi-specific antibodies and multivalent protein therapeutics targeted across a range of indications. zymeworks is focused on accelerating its preclinical biotherapeutics pipeline through in-house research and development programs and strategic collaborations. more information on zymeworks can be found at www.zymeworks.com.

Complete history of Paul Moore stock trades at Zymeworks BC Inc

Zymeworks BC Inc executives and stock owners

Zymeworks BC Inc executives and other stock owners filed with the SEC include:

• Dr. Ali Tehrani,
  Co-Founder, Pres, CEO & Director
• Dr. Anthony J. Polverino Ph.D.,
  Chief Scientific Officer & Exec. VP of Early Devel.
• Neil A. Klompas C.A., CPA, CPA, CA,
  Exec. VP of Bus. Operations & CFO
• Kathryn O'Driscoll,
  Chief People Officer
• Wajida Leclerc,
  VP of HR
• Dr. Jennifer Kaufman-Shaw L.L.B., LLB, Ph.D.,
  VP of Intellectual Property
• Dr. David Poon Ph.D.,
  VP of Bus. Devel. and Alliance Management
• James Daniel Guylain Priour,
  Chief Commercial Officer
• Dr. Neil Josephson M.D.,
  Chief Medical Officer
• Daniel Dex,
  VP of Legal & Corp. Sec.
• Neil Gallagher,
  
• Jeffrey T L Smith,
  EVP & Chief Medical Officer
• Kenneth Galbraith,
  Chair & CEO
• James Priour,
  Chief Commercial Officer
• Carlos Campoy,
  
• Lilly & Co Eli,
  10% owner
• Alessandra Cesano,
  
• Ali Tehrani,
  Chief Executive Officer
• David Kai Yuen Poon,
  See Remarks
• Diana Hausman,
  Chief Medical Officer
• Anthony J. Polverino,
  Chief Scientific Officer
• Nick Bedford,
  Director
• Natalie Sacks,
  Director
• Kenneth J. Hillan,
  
• Lota S. Zoth,
  Director
• Leone D Patterson,
  EVP, Chief Bus & Fin Officer
• Capital, Llc Eco R1,
  10% owner
• Bros. Advisors Lp667, L.P.B...,
  
• Paul Andrew Moore,
  Chief Scientific Officer
• Christopher Astle,
  SVP & Chief Financial Officer
• Neil A Klompas,
  President & COO
• Neil Josephson,
  Chief Medical Officer
• Group, Llc Green Jeremy Red...,
  
• Nancy Davidson,
  
• Susan Mahony,
  
• Hollings Renton,
  
• Derek John Michael Miller,
  
• Troy Cox,
  
• Kelvin Neu,